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Abstract
Background: Adenosquamous carcinoma of the uterine cervix is an infrequent but aggressive subtype of cervical
cancer. A better understanding of its biological behaviour is warranted to define more accurate prognosis and therapeutic
targets. Currently, the blockage of receptor tyrosine kinase (RTKs) activity is an efficient therapeutic strategy for many
different cancers. The objective of this study was to investigate EGFR, PDGFRA and VEGFR2 RTKs overexpression and
activating gene mutations in a cohort of 30 adenosquamous carcinomas of the uterine cervix.
Methods: EGFR, PDGFRA and VEGFR2 immunohistochemistry was performed in all samples, followed by DNA
isolation from the gross macroscopically dissection of the neoplastic area. Screening for EGFR (exons 18–21) and PDGFRA
(exons 12, 14 and 18) mutations was done by PCR – single-strand conformational polymorphism (PCR-SSCP).
Results: Despite the presence of EGFR immunohistochemical positive reactions in 43% (13/30) of the samples, no EGFR
activating mutations in the hotspot region (exons 18–21) were identified. A silent base substitution (CAG>CAA) in EGFR
exon 20 at codon 787 (Q787Q) was found in 17 cases (56%). All PDGFRA immunohistochemical reactions were positive
and consistently observed in the stromal component, staining fibroblasts and endothelial cells, as well as in the cytoplasm
of malignant cells. No activating PDGFRA mutations were found, yet, several silent mutations were observed, such as a
base substitution in exon 12 (CCA>CCG) at codon 567 (P567P) in 9 cases and in exon 18 (GTC>GTT) at codon 824
(V824V) in 4 cases. We also observed the presence of base substitutions in intron 14 (IVS14+3G>A and IVS14+49G>A)
in two different cases, and in intron 18 (IVS18-50insA) in 4 cases. VEGFR2 positivity was observed in 22 of 30 cases
(73.3%), and was significantly associated with lack of metastasis (p = 0.038).
Conclusion: This is the most extensive analysis of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinomas.
Despite the absence of EGFR and PDGFRA activating mutations, the presence of overexpression of these three important
therapeutic targets in a subset of cases may be important in predicting the sensitivity of adenosquamous carcinoma to
specific anti-RTKs drugs.
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Adenosquamous carcinoma (ASC) of the uterine cervix is
a relatively infrequent histological subtype of cervical can-
cer, associated with very aggressive behaviour and reduced
survival rates [1]. ASC histopathological interpretation
remains controversial; theoretically, ASC is a mixture of
malignant glandular and squamous epithelial elements.
However, the practical application of this morphological
criterion is far from being straightforward and the prog-
nostic significance of the histological alterations is con-
tentious and does not exactly predict the clinical
behaviour of ASC [2-4]. The cofactors which contribute to
the progression of HPV-infected cervical carcinoma are
apparently diverse in each type of histogenetic differenti-
ation. The high risk HPV infection persistence is assumed
as a necessary but not sufficient factor to cervical cancer
development, and the genetic and molecular disparities
involved in the carcinoma progression are still poorly
understood [5]. Therefore, a better understanding of ASC
biology is needed to identify the key players and potential
novel therapeutic strategies.
Disruption of the mitogenic signalling mechanisms, par-
ticularly the ones mediated by receptor tyrosine kinases
(RTKs), is a hallmark of the carcinogenic process and cur-
rently constitutes an important therapeutic target group
[6]. RTKs are transmembrane proteins constituted by an
extracellular, a transmembrane, a juxtamembrane, and an
intracellular domain where two kinase regions are located
[7]. Upon growth factor binding, receptor dimerizes and
autophosphorylates its intracellular tyrosine residues that
activate several downstream signalling cascades, like MAP
kinase, PI3-kinase, and JAK/STAT pathways, affecting cel-
lular gene expression [8]. In the neoplastic development
and progression, RTKS are commonly deregulated, and
excessive phosphorylation sustains signal transduction
pathways in an activated state, leading to tumour growth
and progression, proliferation, dedifferentiation, inhibi-
tion of apoptosis, metastasis and angiogenesis [9,10].
Among the distinct RTK classes, class I [e.g. epidermal
growth factor receptor (EGFR)] and class III [e.g. platelet-
derived growth factor receptor-α (PDGFR-α), KIT, vascu-
lar endothelial growth factor receptors 1 (VEGFR1), also
known as Flt-1, and VEGFR2 or Flk-1] [11] have been con-
sistently implicated in solid neoplasm tumourigenesis.
EGFR was the first RTK to be directly linked to human can-
cers [12]. The use of EGFR antagonists, namely mono-
clonal antibodies directed to the extracellular domain,
such as Cetuximab (Erbitux®) and small molecule tyrosine
kinase inhibitors, such as Gefitinib (Iressa®) and Erlotinib
(Tarceva®), have raised great expectations [13]. Recently,
several molecular alterations have been associated with
patient's response to these new anti-EGFR drugs, in partic-
ular, EGFR mutations in hotspot regions of the intracellu-
lar kinase domain (exons 18–21) were predictive of a
positive response to Gefitinib and Erlotinib in a subset of
lung cancer [11]. Positive therapeutic results have also
been reported using KIT and PDGFRA inhibitors such as
Imatinib mesylate (Gleevec®) for gastrointestinal stromal
tumours (GISTs) [14]. Likewise anti-EGFR drugs, specific
gene activating mutations of KIT and PDGFRA gene seem
to predict patients' response to Imatinib [15]. Besides the
use of selective inhibitors, promising therapeutic results
are being attained with multi-target inhibitors such as
Sunitinib (Sutent®), which targets KIT, PDGFR, VEGFR2,
Sorafenib (Nexavar®) that targets KIT, VEGFR2, PDGFR
and intracellular tyrosine kinases, such as BRAF [14] and
Pazopanib, which targets also KIT, PDGFR and VEGFR
[16]. VEGFR2 is not only a mitogenic factor, but essen-
tially an important angiogenic factor; consequently,
blocking its activity potentially enhances therapeutic
response [17]. Recently, we reported absence of KIT
molecular alterations in ASC and provided evidence for
KIT activation through KIT/SCF co-expression in a small
proportion of cases [18], however there are no similar
studies with other RTK therapeutic targets.
The aim of this study was to investigate the presence of
EGFR, PDGFRA and VEGFR2 RTKs aberrations, namely
overexpression and activating gene mutations in a cohort
of 30 adenosquamous carcinomas of the cervix. Accord-
ingly, we intended to assess the potentiality of these RTKs
as therapeutic targets in this aggressive tumour type.
Methods
Materials
This retrospective study comprised a series of 30 patients
with ASC of the uterine cervix, examined and treated at
two Hospitals, retrieved from the files of Araújo Jorge
Hospital and from the Pathology Department of the
School of Medicine of the Federal University of Goiás,
Goiania, in Goias State, Brazil, from 1986 to 2000. All his-
topathological diagnoses were revised by two of the
authors (FCS, MARM) and categorized according to the
WHO classification [19]. The age of the patients ranged
from 24 to 77 years old (mean 49 and median 44.7 years).
Clinico-pathological data was available for 29/30 patients
and included age at diagnosis, lymph-node and/or distant
metastasis, recurrence and overall survival (Table 1). Of
these, 12 patients (41.4%) presented lymph-node and/or
distant metastasis and 2 (6.9%) presented disease recur-
rence. The chosen cut-off for follow-up was 24 months,
leaving 20 cases for analysis (mean 38.5 and median 33
months). The present study was approved by the local
Ethic Committees.
EGFR, PDGFRA and VEGFR2 Immunohistochemistry
EGFR immunohistochemistry analysis of the present
series was previously assessed [20]. For PDGFRA andPage 2 of 8
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was performed according to streptavidin-biotin-peroxi-
dase complex principle, using specific antibodies raised
against PDGFRA (dilution 1:175, Clone C-20, Santa Cruz
Biotechnology, CA), and VEGFR2 (dilution 1:50, Neo-
markers, LabVision Corporation, Fremont, CA), as previ-
ously described [21-23]. In brief, deparaffinised and
rehydrated sections were pre-treated by microwaving in
10 mM citrate buffer (pH 6.0) three times for 5 minutes at
600W. After incubation of VEGFR2 (overnight at 4°C)
and PDGFRA (30 minutes at room temperature) primary
antibody, the secondary biotinylated goat anti-polyvalent
antibody was applied for 10 minutes, followed by incuba-
tion with streptavidin-peroxidase complex. The immune
reaction was visualised by DAB as a chromogen (Ultravi-
sion Detection System Anti-polyvalent, HRP/DAB; LabVi-
sion Corporation, Fremont, CA). Appropriated positive
and negative controls were included in each run: for PDG-
FRA, cutaneous-mucosa transition of the anal region,
namely medium calibre vessels with a muscular layer was
used as positive controls; an angiosarcoma tissue with
immunostaining of the blood vessels was used for
VEGFR2. For negative controls, primary antibodies were
omitted and also replaced by a universal negative control
antibody (CEA, rabbit anti-human, DAKO Corporation,
Carpinteria, CA). All sections were counterstained with
Gill-2 haematoxylin. The immunohistochemical reac-
tions were evaluated as described previously [21]. Briefly,
sections were semi-quantitatively scored as follows: (-),
0% of immunoreactive cells; (+), <5% of immunoreactive
cells; (++), 5–50% of immunoreactive cells; and (+++),
>50% of immunoreactive cells. Samples with scores (-)
and (+) were considered negative, and those with scores
(++) and (+++) were considered positive.
DNA isolation
Serial 10 μm unstained sections of paraffin blocks were
cut, and one adjacent hematoxylin and eosin-stained sec-
tion was taken for identification and selection of the
tumour tissue. Selected areas containing at least 85% of
tumour were marked and, using a sterile needle (Neolus,
25 G-0.5 mm), gross macroscopically dissection was per-
formed. Tissue was placed into a microfuge tube and DNA
isolation was performed using Qiagen's QIAamp® DNA
Micro Kit (Qiagen, Hilden, Germany), as previously
described [18,24].
Table 1: Clinico-pathological features of ASC patients.
Case Age Disease recurrence Presence of metastasis* Follow-up (months) Life status
1 41 No No 64 Alive
2 37 No Yes 22 Alive
3 55 NI NI NI NI
4 59 No Yes 16 Dead
5 46 No No 107 Alive
6 27 No No 28 Alive
7 33 Yes No 36 Alive
8 67 No No 34 Alive
9 40 No No 35 Alive
10 54 No Yes 48 Dead
11 57 Yes No 30 Alive
12 61 No No 9 Alive
13 67 No No 32 Alive
14 38 No No 17 Alive
15 71 No No 5 Alive
16 40 No No 87 Alive
17 40 No No 10 Alive
18 58 No Yes 47 Dead
19 47 No No 22 Alive
20 41 No No 14 Alive
21 39 No Yes 9 Dead
22 40 No Yes 48 Alive
23 45 No No 35 Alive
24 53 No Yes 13 Alive
25 29 No Yes 14 Dead
26 36 No Yes 19 Dead
27 24 No Yes 6 Alive
28 48 No Yes NI Dead
29 56 No No 22 Alive
30 77 No Yes 17 Alive
* Lymph-node and/or distant metastasis; NI, no information available.Page 3 of 8
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Screening for EGFR (exons 18–21) and PDGFRA (exons
12, 14 and 18) mutations was done by PCR – single-
strand conformational polymorphism (PCR-SSCP), as
previously described [21,22,25]. Samples showing a
mobility shift different from the normal pattern were
directly sequenced (Stabvida, Investigation and Services
in Biological Sciences Lda, Oeiras, Portugal), as described
[25]. All positive cases were confirmed twice with a new
and independent PCR amplification, followed by direct
sequencing.
Statistical analysis
Data were stored and analyzed using the SPSS statistical
software (version 16.0, SPSS Inc., Chicago, IL). All com-
parisons were examined for statistical significance using
Pearson's chi-square (χ2) test and Fisher's exact test (when
n < 5), being threshold for significance p values < 0.05.
Survival curve was plotted using the method of Kaplan
and Meier and data compared using the log-rank test.
Results
Assessment of EGFR, PDGFRA and VEGFR2 overexpres-
sion and activating gene mutations was performed in a
cohort of 30 adenosquamous carcinomas of the uterine
cervix. The results are summarized in Table 2 and are
detailed bellow.
EGFR profile
We have previously found that approximately 43% (13/
30) of cases were positive (2+/3+) for EGFR immunohis-
tochemistry (Figure 1A) [20]. In order to determine the
molecular basis of such overexpression, we have per-
formed a mutation analysis of cases. No activating muta-
tions in the hotspot region (exons 18–21) of EGFR gene
were identified. Nevertheless, a silent base substitution
(CAG>CAA) in EGFR exon 20 at codon 787 (Q787Q) was
found in 17 cases (56%) (Table 3).
No statistically significant correlations were observed
between EGFR gene alteration and the clinico-pathologi-
cal parameters (data not shown).
Table 2: Molecular alterations of EGFR, PDGFRA and VEGFR2 in ASC patients.
Case EGFR PDGFRA VEGFR2
Mutations IHC* Mutations IHC IHC
1 Q787Q - P567P; V824V; IVS18-50insA +++ ++
2 Normal +++ Normal +++ -
3 Q787Q +++ V824V; IVS18-50insA +++ +++
4 Q787Q +++ V824V; IVS18-50insA +++ +++
5 Q787Q +++ V824V; IVS18-50insA +++ +++
6 Normal + Normal +++ +++
7 Q787Q +++ P567P; IVS14+3G>A +++ ++
8 Q787Q - Normal +++ +++
9 Normal - Normal +++ +++
10 Normal +++ P567P +++ +++
11 Normal - P567P np +++
12 Q787Q - Normal +++ +++
13 Q787Q - Normal ++ +++
14 Normal ++ Normal +++ ++
15 Q787Q + Normal +++ +++
16 Normal +++ P567P +++ +
17 Q787Q - P567P ++ +++
18 Normal - Normal +++ +
19 Q787Q +++ Normal +++ ++
20 Q787Q - Normal +++ +++
21 Normal + P567P np +++
22 Normal ++ P567P +++ +
23 Normal +++ Normal ++ ++
24 Q787Q - Normal ++ +
25 Q787Q + IVS14+49G>A +++ +
26 Q787Q - P567P +++ +++
27 Normal - Normal np ++
28 Q787Q ++ Normal ++ +
29 Q787Q - Normal +++ +
30 Normal +++ Normal ++ +++
IHC: Immunohistochemistry; *: previously reported in [20]; np: not possible due to tissue limitation.Page 4 of 8
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PDGFRA immunohistochemical analysis was only possi-
ble in 27 out of 30 cases, all of them being positive for
PDGFRA expression. Six cases showed moderate positivity
(2+) and 21 showed strong positivity (3+) (Figure 1B).
Positive immunoreactions were observed in the cyto-
plasm of malignant cells, and were consistently observed
in the stromal component, staining fibroblasts and
endothelial cells.
Mutation analysis of PDGFRA hotspot exons 12, 14 and
18 of all 30 cases, revealed absence of activating muta-
tions. Yet, we observed several silent mutations, such as a
base substitution in exon 12 (CCA>CCG) at codon 567
(P567P) in 9 cases and in exon 18 (GTC>GTT) at codon
824 (V824V) in 4 cases (Table 2). We also observed base
substitutions in intron 14 (IVS14+3G>A and
IVS14+49G>A) (Figure 2), in two different cases, and in
intron 18 (IVS18-50insA) in 4 cases (Table 3).
Since all cases were positive for PDGFRA expression, anal-
ysis of correlations with the clinico-pathological data was
not performed.
VEGFR2 profile
VEGFR2 immunohistochemical positivity was observed
in 22 of 30 cases (73.3%), with 6 cases showing moderate
expression (2+) and 16 cases presenting strong positive
immunoreaction (3+). Positive immunoreactions were
exclusively observed in the cytoplasm of malignant cells.
No stromal positive reaction was identified, but faint pos-
itive staining was observed in a few endothelial cells sur-
rounding the neoplastic cells (Figure 1C).
Correlation analysis between VEGFR2 expression and
clinico-pathological data revealed a significant associa-
tion between VEGFR2 overexpression and lack of metasta-
sis (p = 0.038). No associations between VEGFR2
Table 3: Sequence variants of EGFR and PDGFRA gene in ASC patients.
Gene (exon) Nucleotide Change Aminoacid Substitution N° of cases dbSNP
EGFR (exon 20) 2361 G>A Q787Q 17 rs1050171
PDGFRA (exon 12) 1701 G>A P567P 9 rs1873778
PDGFRA (exon 14) 2002+3G>A IVS14+3G>A 1 Not yet described
2002+49G>A IVS14+49G>A 1 Not yet described
PDGFRA (exon 18) 2472 C>T V824V 4 rs2228230
2449-50insA IVS18-50insA 4 rs3830355
dbSNP: Single Nucleotide Polymorphism database http://www.ncbi.nlm.nih.gov/SNP/
Immunohistochemical expression of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinomaFigure 1
Immunohistochemical expression of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma. A) 
EGFR positive immunoreaction decorating the cytoplasm of malignant cells. No stromal or endothelial positive reactions were 
observed (original magnification ×40). B) PDGFRA positive immunoreaction was observed in the cytoplasm of malignant cells. 
PDGFRA positive reaction was also constantly observed in the stromal component, decorating fibroblasts and endothelial cells 
(original magnification ×40). C) VEGFR2 positive immunoreaction was in the cytoplasm of malignant cells. No stromal positive 
reaction was identified, but positive staining was observed in a few endothelial cells surrounding the neoplastic cells (original 
magnification ×40).Page 5 of 8
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were found (data not shown).
Discussion
Advances in the knowledge of the altered molecular
events in neoplastic cells have paved the way to the dis-
covery of new and promising targets and drugs for cancer
treatment. Three of these potential targets are EGFR,
PDGFR and VEGFR2, which have important roles in
tumour proliferation and angiogenesis. The results herein
reported aimed to identify molecular alterations in these
therapeutic targets predictive of a positive response to
selective inhibitors in cervical adenosquamous carcinoma
(ASC).
Overexpression of EGFR has been reported to be frequent
in cervical cancer, ranging from approximately 25–70%
[26-31]. Most studies have focused the analysis squamous
cell carcinomas [26-31]. We and others have shown that
in adenosquamous carcinoma EGFR overexpression var-
ies from 33–43% of cases, being in the range of overall
cervical cancer [20,28,29]. Despite the presence of EGFR
overexpression, we showed that none of adenosquamous
carcinomas harbour EGFR gene activating mutations.
Nevertheless, a silent base substitution (CAG>CAA) in
EGFR exon 20 at codon 787 (Q787Q) was found in 17
cases (56%). This polymorphism is a known single nucle-
otide polymorphism (SNP), which frequencies vary in dif-
ferent populations, being the G allele more frequent in
Asians and African Americans, whereas the A allele is
more frequent in Europeans (rs1050171, NCBI SNP data-
base). The implication of this SNP in EGFR function is still
unclear. Taguchi et al, analysing head and neck squamous
cell carcinomas did not observe any significant differences
at EGFR mRNA and protein levels in cell lines harbouring
different genotypes, despite the described higher sensitiv-
ity of (G/A) heterozygous when compared with (G/G)
homozygous cell lines to Gefitinib [32]. Recently, Arias-
Pulido et al, also described the absence of EGFR activating
mutations in a large series of 89 cervical cancers, including
75 squamous cell carcinomas and 5 adenocarcinomas
[33]. The mechanism driving EGFR overexpression in ade-
nosquamous carcinomas remains to be determined. Pre-
vious studies have shown that EGFR could be regulated by
EGFR gene amplification [28] or by HPV oncoproteins,
namely the HPV E5 and E6, which are linked with
increased EGFR levels, through inhibition of EGFR inter-
nalization and degradation [34,35].
Several clinical trials are evaluating the efficacy of anti-
EGFR therapies for advanced cervical cancer [6]. Studies of
cetuximab-based therapy, either in monotherapy or in
association with radiotherapy are ongoing for treatment
of recurrent and early cervical carcinoma [Gynecologic
Oncology Group (GOG)-0227E; GOG-9918]. A multi-
center phase II trial evaluated the clinical outcomes of
Gefitinib-based therapy in 30 patients with recurring loco
regionally advanced or metastatic cervical cancer [36].
There were no objective responses, however, 1/5 of
patients exhibited stable disease, and tumour response
was not correlated with EGFR immunohistochemistry lev-
els [36]. These results are not surprising, since it is known
that in cancer patients, particularly those with lung cancer,
it is the presence of EGFR tyrosine kinase activating muta-
tions rather than EGFR immunoreactivity that is associ-
ated with a marked clinical response [37]. Since our
results indicate the absence of EGFR activating mutations
in ASC, we would predict that Gefitinib, as well as Erlo-
tinib, in monotherapy are unlikely to be effective in these
patients.
Very few studies addressed the role of PDGFRA in cervical
carcinogenesis [38-40]. Taja-Chayeb et al, have analyzed a
total of 36 cases, which included 4 adenosquamous carci-
nomas. The authors reported overexpression of PDGFRA
in neoplastic cells in approximately 42% cases, and a less
frequent overexpression in stromal cells (~8%) [38]. In a
recent and elegant study, Pietras K et al, showed that PDG-
FRA is almost ubiquitously expressed in the stroma of cer-
vical cancers, but is much less expressed in neoplastic cells
[40]. In the present study, we detected PDGFRA overex-
pression in all cases, either in the neoplastic or stromal
component of tumours. These discrepancies could be due
in part to the different antibodies used and to distinct his-
tological subtypes analysed. In the present study, no acti-
vating mutations were observed, regardless of the
presence of several genetic variants, many of them being
known as genetic polymorphisms. Our results are in
agreement with the described absence of activating muta-
tions in 17 cervical carcinomas [38]. Nevertheless, recent
Electropherogram of part of PDGFRA sequenceFigu e 2
Electropherogram of part of PDGFRA sequence. DNA 
sequencing of an intronic base substitution (IVS14+49G>A) 
in PDGFRA intron 14. Arrow indicates G to A transition at 
2002 base pairs.Page 6 of 8
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carcinomas tumour samples, showed significant thera-
peutic benefits of Imatinib-based therapy [40,41].
VEGFR2 is widely distributed in human tissues and
tumours [42]. These receptors were originally thought to
be only present in activated endothelial cells; however,
recent immunohistochemical studies showed that
VEGFR2 is also present in cancer cells and that transloca-
tion of phosphorylated VEGFR2 to the nuclei is a frequent
event presumably being linked to an existing autocrine
VEGF/VEGFR2 loop [42-44]. An interesting recent report
suggests that VEGFR2 is a marker of precancerous stem
cells [45]. To the best of our knowledge, there are no
reports on VEGFR2 expression in cervical adenosquamous
carcinomas. We showed presence of neoplastic VEGFR2
expression in approximately 2/3 of cases. Our data
showed an association between VEGFR2 overexpression
and lack of metastasis. This apparently paradox may sug-
gest that other alternative molecules can drive the meta-
static spread in this rare type of cervical cancer, even when
VEGFR2 is overexpressed in the cancer cell cytoplasm, as
observed in the present study. Several clinical trials of
anti-VEGFR2 drugs are being conducted in cervical cancer
[6]. Sorafenib, is being assessed in a phase I/II clinical trial
in combination with radiotherapy and cisplatin (DDP-
DRO-002) [46]. Presently, simultaneous inhibition of
several receptors tyrosine kinases is believed to optimize
the overall therapeutic benefit associated with molecular
targeted anticancer agents [47]. A clinical study is ongoing
to evaluate the efficacy and safety of Pazopanib and Lap-
atinib, a dual tyrosine kinase inhibitor of EGFR and
HER2, alone or in combination in patients with meta-
static cervical cancer (VEG105281) [48].
Conclusion
In conclusion, the present study is most the comprehen-
sive analysis of EGFR, PDGFRA and VEGFR2 oncogenes in
adenosquamous carcinoma. We observed absence of acti-
vating mutations in EGFR and PDGFRA oncogenes,
despite the presence of protein overexpression. VEGR2
was frequently overexpressed and associated with lack of
metastasis. The current molecular profiling can be valua-
ble for future selection of adenosquamous cervical carci-
noma therapeutic options.
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